focus -WSS

focus

author：explore 2025-09-03 09:28:06 - browse：177

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Readout Newsletter: Biotech news, including Moderna's Covid vaccine

WSS

Physician executives need more than on

Analysis of telehealth claims data suggest service duplication

Bristol 'take

3 questions for the future of Biden's cancer moonshot

Bristol 'take

A virus, fished out of a lake, may have saved a man’s life

entertainment

focus

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

The United States is paying nearly triple for new Covid vaccines

Moonlake's readout produced a cash windfall. Risks remain

Bill would stop addiction treatment from triggering child abuse inquiry

Virginia high school admissions case could be legal follow

Bristol 'take

Drug repurposing or repositioning? The language matters

Congress extends some pandemic preparedness programs

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Wikipedia

Why Charlie Gard's case is so disturbing to Americans

Physician executives need more than on

European officials brace for rough respiratory virus season

RSV injection headlines need to be accurate for good uptake

With Roe v Wade overturned, abortion providers work to adapt

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

focus

leisure time

Wikipedia

entertainment